Drug · CHEMBL960
LEFLUNOMIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LEFLUNOMIDE. Drugs and targets, record CHEMBL960. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL960
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Arava, Leflunomide medac, Leflunomide ratiopharm, Leflunomide teva, Leflunomide zentiva (previously leflunomide winthrop), Repso
- ChEMBL
- Other names
- HWA-486, L04AA13, Leflunomida, Leflunomide medac, Leflunomide ratiopharm, Leflunomide teva, Leflunomide winthrop, NSC-677411, NSC-759864, Repso, SU-101, SU101, SULOL
- ChEMBL
- Open Targets' highest stage
- Approval, for 4 of its 48 diseases, from DailyMed, EMA Human Drugs and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| DHODH | Dihydroorotate dehydrogenase (quinone), mitochondrial | Dihydroorotate dehydrogenase inhibitor | INHIBITOR | https://conductscience.org/library/genes/1723 |
Source ChEMBL
Diseases48
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| rheumatoid arthritis | Approval | DailyMed and EMA Human Drugs | 39 | 21 | https://conductscience.org/library/drugs?q=MONDO_0008383 |
| COVID-19 | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0100096 |
| immunoglobulin G4-related sclerosing disease | Unknown | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0017287 |
| plasma cell myeloma | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0009693 |
| smoldering plasma cell myeloma | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005235 |
| systemic lupus erythematosus | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0007915 |
| Takayasu arteritis | Unknown | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0017991 |
| lupus nephritis | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005556 |
| psoriatic arthritis | Approval | EMA Human Drugs | 4 | 1 | https://conductscience.org/library/drugs?q=MONDO_0011849 |
| B-cell non-Hodgkin lymphoma | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0015759 |
1 to 10 of 48Source Open Targets
See all 48 diseasesTrials89
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01709578 | To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET) | Phase 3 | 546 | 2017-08-08 | leflunomide | Its name | ClinicalTrials.gov |
| NCT01172639 | Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis. | Phase 4 | 400 | 2018-12-10 | leflunomide | Its name | ClinicalTrials.gov |
| NCT00422227 | Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region | Phase 4 | 300 | 2010-08-30 | leflunomide | Its name | ClinicalTrials.gov |
| NCT03649061 | COBRA-Slim With or Without Fast Access to TNF Blockade for Remission Induction in Early RA | Phase 4 | 276 | 2025-06-19 | leflunomide | Its name | ClinicalTrials.gov |
| NCT02057250 | To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis | Phase 3 | 217 | 2017-06-20 | leflunomide | Its name | ClinicalTrials.gov |
| NCT03739853 | Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial | Phase 4 | 192 | 2025-11-26 | leflunomide | Its name | ClinicalTrials.gov |
| NCT02930343 | Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy | Phase 3 | 136 | 2021-06-10 | leflunomide | Its name | ClinicalTrials.gov |
| NCT01941095 | A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis | Phase 3 | 100 | 2018-11-13 | leflunomide | Its name | ClinicalTrials.gov |
| NCT02373202 | A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA) | Phase 3 | 91 | 2018-01-30 | leflunomide | Its name | ClinicalTrials.gov |
| NCT00834418 | Leflunomide 20 mg Tablets Under Fasting Conditions | Phase 1 | 84 | 2009-08-18 | leflunomide | Its name | ClinicalTrials.gov |
1 to 10 of 89
See all 89 trialsComparisons in its trials16
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| ETN/MTX vs DMARD/MTX: serious adverse events | 6 of 197 | 3 of 103 | 300 | NCT00422227 | Trial comparisons |
| Group 1- MTX+LEF+HCQ vs Group 2- MTX+SSZ+HCQ: Number of Patients Achieving Good EULAR Response at the End of 12 Weeks | 40 of 68 | 37 of 68 | 136 | NCT02930343 | Trial comparisons |
| Group 1- MTX+LEF+HCQ vs Group 2- MTX+SSZ+HCQ: deaths from any cause | 0 of 68 | 0 of 68 | 136 | NCT02930343 | Trial comparisons |
| Group 1- MTX+LEF+HCQ vs Group 2- MTX+SSZ+HCQ: serious adverse events | 0 of 68 | 0 of 68 | 136 | NCT02930343 | Trial comparisons |
| Standard COBRA-Slim Induction vs COBRA-Slim Bio-induction: Proportion of Patients in Remission Defined as DAS28CRP<2.6 | 38 of 55 | 30 of 55 | 110 | NCT03649061 | Trial comparisons |
Standard COBRA-Slim Induction vs COBRA-Slim Bio-induction: Proportion of Insufficient Responders Achieving Remission (DAS28CRP<2.6) 28 Weeks After Randomization (Short Term Efficacy) to Either COBRA-Slim Bio-Induction or Standard COBRA-Slim Induction | 24 of 55 | 32 of 55 | 110 | NCT03649061 | Trial comparisons |
| Standard COBRA-Slim Induction vs COBRA-Slim Bio-induction: deaths from any cause | 1 of 55 | 1 of 55 | 110 | NCT03649061 | Trial comparisons |
| Standard COBRA-Slim Induction vs COBRA-Slim Bio-induction: serious adverse events | 4 of 55 | 5 of 55 | 110 | NCT03649061 | Trial comparisons |
| Tocilizumab Monotherapy vs Tocilizumab + Methotrexate or Other Non-Biologic DMARDs: serious adverse events | 2 of 31 | 5 of 66 | 97 | NCT01941095 | Trial comparisons |
| Acupuncture vs Control: ACR50 Response Rate at 3 Months | 2 of 6 | 1 of 4 | 10 | NCT01619176 | Trial comparisons |
1 to 10 of 16
See all 16 comparisons in its trialsPapers from its trials54
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL960
GET https://conductscience.org/api/drugs/v1/CHEMBL960/diseases?page=2